Your search returned 2 results. Subscribe to this search

|
1. Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial

by Waksman, Ron.

Citation: Lancet. 387(10013):31-9, 2016 Jan 2..Institution: MedStar Heart & Vascular Institute.Publication: Journal Article.Article type: Clinical Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't.Full author list: Haude M; Ince H; Abizaid A; Toelg R; Lemos PA; von Birgelen C; Christiansen EH; Wijns W; Neumann FJ; Kaiser C; Eeckhout E; Lim ST; Escaned J; Garcia-Garcia HM; Waksman R.UI/PMID: 26470647.Online Access: Click here to access online Digital Object Identifier: http://dx.doi.org/10.1016/S0140-6736(15)00447-X (Click here)
2. Six-month IVUS and two-year clinical outcomes in the EVOLVE FHU trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent

by Weissman, Neil J.

Citation: Eurointervention. 9(3):308-15, 2013 Jul..Institution: MedStar Heart & Vascular Institute.Publication: Journal Article.Article type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't.Full author list: Meredith IT; Verheye S; Weissman NJ; Barragan P; Scott D; Valdes Chavarri M; West NE; Kelbaek H; Whitbourn R; Walters DL; Kubica J; Thuesen L; Masotti M; Banning A; Sjogren I; Stables RH; Allocco DJ; Dawkins KD.UI/PMID: 23872647.Digital Object Identifier: http://dx.doi.org/10.4244/EIJV9I3A52 (Click here)

Powered by Koha